Spinal Muscular Atrophy is the leading genetic cause of death for infants. However you are impacted, we have information for you.
News Feed
Genentech Releases Evrysdi™ FDA Approval Letter to the SMA Community
Dear SMA Patient Advocacy Community, As part of our ongoing partnership and following your request to receive updates about the risdiplam clinical ...
Genentech Receives FDA Approval of Evrysdi (risdiplam) for the Treatment of SMA
Genentech, a member of the Roche Group, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Evrysdi (risdiplam) ...
Cure SMA Launches New Medical Alert Bracelet Support Program
Along with funding SMA research and care, Cure SMA provides thousands of individuals and families with vital support and resources that help ...
Community Spotlight
Community Spotlight: Avery’s Diagnosis from Newborn Screening
July 2020 marks the 2-year anniversary of when the U.S. Secretary of Health and Human Services recommended that SMA be added ...
Community Spotlight: Ben Lou’s Formula for Life
Ben Lou is a 17-year-old from San Diego who is fluent in both English and Chinese. He is a math whiz ...
Community Spotlight: Raising Money for Cure SMA, One Cookie at a Time
Dana Perrella is a 9-year-old on a mission to raise $50,000 for spinal muscular atrophy (SMA) research in 2020. She began ...
Cure SMA is committed to local support.
Find resources or a treatment site in your area.
Since 1984, we’ve invested $82 million in the research that has made today’s breakthroughs possible. We advance a comprehensive research program, attacking SMA from all sides.
The Cure SMA Care Center Network
Local, evidenced-based care centers, designed to develop an evidence-based standard of care to improve the lives of all those affected by SMA.